ELOVL5 and breast carcinoma: Moreover, treatment with the inhibitors of TGF-β receptors (LY2157299 and LY2109761) alleviated the repression of proliferation induced by Elovl5 silencing in breast cancer cells (Fig. 4J, K and Supplementary Fig. S4I).